October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with …

FDA warns about the risk of HBV reactivation in patients treated with DAA for HCV-infection Read more »

July 31, 2015 – This week, just in time for World Hepatitis Day on July 28, the American Food and Drug Administration (FDA) approved Daclatasvir (Daklinza)  for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. In addition, the …

A very exciting week for patients with hepatitis C viral (HCV) infections of the genotypes 3 and 4 Read more »

July 10, 2014 – The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has endorsed daclatasvir (Daklinza, Bristol-Myers Squibb) to treat adults with chronic hepatitis C virus (HCV) infection, in combination with other drugs. Daclatasvir is …

EMA: EU Panel Endorses Daclatasvir (Daklinza) for Chronic Hepatitis C Infection Read more »